APEPTICO - Innovation in peptide drugs
APEPTICO - Innovation in peptide drugs
APEPTICO is an innovative biotech company that develops new peptide-based medicinal drugs for the therapeutic and prophylactic treatment of severe and chronic diseases.
Our mission is to translate structural elements of well-characterised proteins and biopharmaceuticals into pre-clinically and clinically validated peptides.
All our products address highly profitable and growing markets.
Read most recent news from APEPTICO
05th August, 2010, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced completion of a €3 million financing round. 23rd February, 2010. APEPTICO's lead molecule AP301 has been validated in the experimental lung transplantation model to prevent ischemia reperfusion injury. 10th February, 2010. APEPTICO granted Orphan Drug Designation by FDA for development compound AP301. APEPTICO will present the company and development products at the BioSquare (February 1st-2nd, 2010) and Bio-Europe Spring (March 8th-10th, 2010). Meet APEPTICO at the Science4Life Messe in Frankfurt (October 22nd, 2009) and the Bio-Europe in Vienna (November 2nd-4th, 2009). 08th September, 2009. APEPTICO presents its lead product AP301 at the Annual Congress of the European Respiratory Society in Vienna, Austria. 20th July, 2009. APEPTICO granted Orphan Medicinal Product Designation by EMEA for lead product AP301.